<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04464616</url>
  </required_header>
  <id_info>
    <org_study_id>spinal additives in CS</org_study_id>
    <nct_id>NCT04464616</nct_id>
  </id_info>
  <brief_title>Adding Different Additives to Bupivacaine-fentanyl Mixture in Spinal Anesthesia for Cesarean Section</brief_title>
  <official_title>The Effect of Adding Dexmedetomidine or Dexamethasone to Bupivacaine-Fentanyl Mixture in Spinal Anesthesia for Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal anesthesia is widely used in cesarean section, but it is associated with high&#xD;
      incidence of side effects. To reduce the occurrence of side effects, intrathecal adjuvant was&#xD;
      recommended to use in spinal anesthesia, with the aim in reducing the dose of intrathecal&#xD;
      local anesthetic, which can subsequently decrease the incidence of spinal-induced side&#xD;
      effects and prolong postoperative analgesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal anesthesia is widely used in cesarean section, but it is associated with high&#xD;
      incidence of side effects. To reduce the occurrence of side effects, intrathecal adjuvant was&#xD;
      recommended to use in spinal anesthesia, with the aim in reducing the dose of intrathecal&#xD;
      local anesthetic, which can subsequently decrease the incidence of spinal-induced side&#xD;
      effects and prolong postoperative analgesia.Many augmentation strategies for intrathecal&#xD;
      analgesia have been proposed. A meta-analysis by Popping et al. concluded that the&#xD;
      concomitant use of an opioid such as fentanyl intrathecally allows the reduction in the dose&#xD;
      of local anesthetic, while augmenting its analgesic potency thereby decreasing its adverse&#xD;
      effects.&#xD;
&#xD;
      Dexamethasone relieves pain through reducing inflammation and blocking of nociceptive C-&#xD;
      fibers transmission and by suppressing neural ectopic discharge. Post-operative analgesic&#xD;
      effectiveness and duration was prolonged when dexamethasone was used as an adjunct for&#xD;
      peripheral nerve blocks. Recent studies reported no complications associated with intrathecal&#xD;
      dexamethasone.&#xD;
&#xD;
      Dexmedetomidine (DEX) is a potent, selective α2 adrenergic agonist and when given&#xD;
      intrathecally, it exerts its analgesic effect via stimulating spinal α2 receptors. Wu et al.,&#xD;
      in their meta-analysis showed that addition of intrathecal DEX significantly increased the&#xD;
      duration of postoperative analgesia and reduced analgesic consumption. The increase in&#xD;
      duration of postoperative analgesia is dose dependent but with increase in the incidence of&#xD;
      bradycardia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Actual">January 20, 2021</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time for the first request of rescue analgesia</measure>
    <time_frame>postoperative first day</time_frame>
    <description>time for the first request of rescue morphine analgesia at dose of 3 mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale</measure>
    <time_frame>postoperative first day</time_frame>
    <description>Numerical Rating Scale (NRS) for pain that ranged from (0 = no pain) to (10 = intolerable pain). If score is &gt;3 will need analgesia in the form of morphine 3 mg will be given till NRS decreases to ≤3. NRS will be assessed and recorded immediately postoperative, 2, 4, 8, 12, 18, 24 h after the operation, by an anesthesiologist, who is blinded to the study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal satisfaction</measure>
    <time_frame>postoperative first day</time_frame>
    <description>Maternal satisfaction will be evaluated on a 0-3 score (0 = poor, 1 = fair, 2 = good, and 3 = excellent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal outcome</measure>
    <time_frame>time of delivery of fetus</time_frame>
    <description>Neonatal outcome will be assessed in terms of Apgar score.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>spinal anesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + normal saline (0.5 ml).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine group):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>spinal anesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + 5 μg dexmedetomidine in a volume of (0.5 ml).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>spinal anaesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + 2 mg dexamethasone in a volume of 0.5 ml).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>spinal anaesthesia</intervention_name>
    <description>spinal anaesthesia will be performed with the patient in sitting position at the L3-L4 or L4-L5 interspaces with a 25 or 27 G spinal tip needle with the study drug in the total volume of 3 ml.</description>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <arm_group_label>Dexmedetomidine group):</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>intrathecal anaesthesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  90 parturient&#xD;
&#xD;
          -  the statue of American Society of Anesthesiologists' physical class II&#xD;
&#xD;
          -  prepared for an elective cesarean section.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 35kg/m2&#xD;
&#xD;
          -  gestational age &lt; 28 weeks&#xD;
&#xD;
          -  diabetes or gestational diabetes&#xD;
&#xD;
          -  hypertension or pre-eclampsia&#xD;
&#xD;
          -  contraindications to spinal anesthesia&#xD;
&#xD;
          -  height less than 160 Cm&#xD;
&#xD;
          -  history of psychiatric disease&#xD;
&#xD;
          -  taking α-receptor antagonist drugs -a history of allergy to the study drugs-&#xD;
&#xD;
          -  excessive hemorrhage needing transfusion.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tarek Abdel Hay</name>
      <address>
        <city>Tanta</city>
        <state>El Gharbyia</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>tarek abdel hay mostafa</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

